Facile Synthesis of Non-nucleoside Compounds Starting from α -Chlorocarbenium Ions and Isocyanates as Potential HIV-1 Reverse Transcriptase Inhibitors

Atef A. Hamed, Ibrahim F. Zeid, and Alaa A. Manaa

Chemistry Department, Faculty of Science, Menoufia University, Shebin El Koam, Egypt

Reprint requests to Dr. Atef A. Hamed. Fax: +20-48-2235689. E-mail: atef2000_99@yahoo.com

Z. Naturforsch. **2009**, *64b*, 555 – 564; received February 12, 2009

Dedicated to Professor Volker Jaeger on the occasion of his 65th birthday

Chloro(phenyl)carbenium hexachloroantimonate salts react with isocyanates to afford either isoindolium (**1**) or benzoxazinium salts (**2**). Addition of one equivalent of alcohol to **2** led, after hydrolysis with aq. NaOH, to the formation of benzoxazin-2-ones **3**. Treatment with a large excess of alcohol transformed the salts **1** and **2** to the corresponding isoindol-1-ones **11** and the isocyanates **5**, respectively. Reaction of **5** with primary amines furnished the urea derivatives **6** in good yield. The biological activity of **6a–o** against HIV-1 was determined.

Key words: α -Chlorocarbenium Salts, Isocyanates, Isoindoles, Urea Derivatives, Benzoxazinones, Reverse Transcriptase Inhibitors

Introduction

The life cycle of HIV-1 has been extensively studied, and a number of stages identified for possible intervention to prevent viral replication. Clinically relevant agents which have been successfully developed are: a) nucleoside reverse transcriptase inhibitors (NRTIs), for example zidovudine (AZT), didanosine (DDI), zalcitabine (DDC), stavudine (D4T), lamivudine (3TC), abacavir (ABC), emtricitabine, and tenofovir disoproxil; b) non-nucleoside reverse transcriptase inhibitors (NNRTIs) such as atevirdine, capravirine, efavirenz, emivirine, lodenosine, nevirapine, etravirine, rilpivirine, loviride, delavirdine, and quinotaline; c) protease inhibitors (PIs) *e. g.*, atazanavir, brexanavir, fosamprenavir, lopinavir, darunavir, nelfinavir, ritonavir, saquinavir, tipranavir, amprenavir, and indinavir; d) integrase inhibitors like raltegravir and elvitegravir; e) entry (fusion) inhibitors such as aplaviroc, enfuvirtide, maraviroc, vicriviroc, and ibalizumab; f) maturation inhibitors, for example bevirimat and vivecon. Several others are in preclinical or clinical development. From these compounds, thirty anti-HIV drugs have been approved and licensed for clinical use in the USA by the Food and Drug Administration (FDA). Four of them, namely, nevirapine [1, 2], delavirdine [3, 4], efavirenz [5] and – the first to be ap-

proved in 2008 – etravirine [6, 7] belong to the group of NNRTIs. These compounds have gained a definitive place in the treatment of HIV-1 infections. Starting from HEPT [8] and TIBO [9] derivatives, more than 40 structurally different classes of compounds have been identified as NNRTIs. However, as with all current HIV therapies, drug incompatibilities, adverse effects, the emergence of resistant viral strains or of cross-resistance continue to limit the clinical usefulness of the NNRTIs. Therefore, additional NNRTIs are needed that might have improved pharmacokinetics, limited toxicities, and more favorable resistance mutation profiles.

In continuation of our previous work on searching antiviral drugs [10, 11], we report in this communication on a facile access to a new series of urea, isoindole and benzoxazine derivatives, analogs of trovirdine [PETT (LY300046)] [12], thiazoloisoindolinone (BM +51.0836) [13], and efavirenz (DMP 266) [5] compounds.

Results and Discussion

The starting materials, 1-oxoisoindolium salts (**1**), could be prepared as described in the literature [14] from the reaction of alkyl- or electron-rich arylisocyanates with α -chlorocarbenium salts, whereas the formation of benzoxazinium hexachloroantimon-

Scheme 1.

ate (**2**) resulted only from treatment of electron-deficient carbenium salts with electron-rich aryloisocyanates (Scheme 1). For instance, addition of a solution of $SbCl_5$ in CH_2Cl_2 to a cold ($-30\text{ }^\circ\text{C}$) mixture of *p*-tolylisocyanate and *p*-chlorobenzotrichloride resulted in the formation of **2**. This salt is extremely sensitive toward nucleophiles. Dropwise addition of one molar equivalent of alcohol afforded, after hydrolysis with aq. $NaOH$, 3,1-benzoxazin-2-ones **3**, analogs of efavirenz. During purification of **3b** by column chromatography on silica gel, using 15% $EtOAc/n$ -hexane as eluent, the dibenzodiazocine **4** was isolated in 5% yield. The formation of **4** is probably due to condensation of two molar equivalents of 2-amino-4'-chloro-4-methylbenzophenone which is formed as a result of partial hydrolysis of **2** [14].

Addition of a large excess of an alcohol in one portion to a cold ($-10\text{ }^\circ\text{C}$) suspension of **2** in absolute CH_2Cl_2 led to the formation of the isocyanates **5a, b** as yellow oils which could be used without further purification. Treatment of **5** with primary amines in warm diethyl ether gave the corresponding urea derivatives **6a–o** in good yield, analogs of urea-PETT compounds [15, 16]. When **6** was exposed to a few drops of conc. H_2SO_4 or $SbCl_5$ in CH_2Cl_2 , quinazolinone **8** was obtained instead of the expected 4-alkoxy derivative **7** (Scheme 2).

The structure assignment of the prepared compounds is based, beside elemental analyses, on their spectral (IR, 1H , ^{13}C NMR) data. The IR spectra of **1b** (Nujol) showed absorption bands at 1757 and 1811 cm^{-1} for $(C=N^+)$ and $(C=O)$ groups, whereas

compounds **3a, b** exhibited bands in the ranges of $1720\text{--}1735$ and $3350\text{--}3413\text{ cm}^{-1}$ due to $C=O$ and NH absorptions, respectively. The urea derivatives **6a–o** showed in their IR spectra (KBr) absorption bands in the ranges $1664\text{--}1702$ and $3348\text{--}3380\text{ cm}^{-1}$ for $C=O$ and (NH) groups. In the ^{13}C NMR ($CDCl_3$) spectra, the ketal carbons of **6a–o** resonated around 101.2 ppm .

Addition of a large excess of alcohol to a cold ($-10\text{ }^\circ\text{C}$) suspension of 3-phenyl-2-substituted-1-oxoisindolium salts **1** in CH_2Cl_2 furnished 3-alkoxy derivatives **11a–f** in moderate yield, whereas with traces of water or better aqueous base, 3-hydroxyisindoles (**9a, b**) were obtained. Reduction of the latter compounds by $H_2/Pd/C$ in absolute methanol afforded isindol-1-ones **10a, b** (Scheme 3). The *N*-allyl group of **9b** is converted to the *n*-propyl group during the reduction process. The constitutions of isindoles **9, 10** and **11** were derived from spectroscopic data. IR spectra of **9a, b** showed absorption bands in the ranges $1686\text{--}1690$ and $3280\text{--}3290\text{ cm}^{-1}$ for $C=O$ and OH groups, whereas compounds **10a, b** and **11a–f** displayed bands in the range of $1674\text{--}1703\text{ cm}^{-1}$ for the carbonyl groups. In the 1H NMR ($CDCl_3$) spectra of **9a, 10a** and **11a–c** diastereotopic CH_2 protons were observed. The OH groups of compounds **9a, b** appeared in the range of $4.23\text{--}4.86\text{ ppm}$, whereas the 3-H protons of **10a, b** resonated as a singlet at $5.35\text{--}5.46\text{ ppm}$. The ^{13}C NMR spectra of **9, 10** and **11** displayed peaks for C-3 around $91.6, 64.2$ and 94.6 ppm , respectively. The carbonyl carbons of the isindole derivatives resonated between 167.0 and 168.3 ppm .

Comp.	R	R ¹	Comp.	R	R ¹
3a	2-Cl-C ₆ H ₄ -CH ₂		6g	CH ₃ CH ₂	2-furanyl-CH ₂
3b	CH ₃ CH ₂ -OCH ₂ CH ₂		6h	CH ₃ CH ₂	4-CH ₃ CH ₂ O-C ₆ H ₄
5a	CH ₃ CH ₂		6i	CH ₃ CH ₂	4-CH ₃ O-C ₆ H ₄
5b	CH ₂ =CHCH ₂		6j	CH ₂ =CHCH ₂	H
6a	CH ₃ CH ₂	H	6k	CH ₂ =CHCH ₂	CH ₂ =CHCH ₂
6b	CH ₃ CH ₂	CH ₂ =CHCH ₂	6l	CH ₂ =CHCH ₂	C ₆ H ₅ CH ₂
6c	CH ₃ CH ₂	CH(CH ₃)C ₆ H ₅	6m	CH ₂ =CHCH ₂	4-CH ₃ O-C ₆ H ₄
6d	CH ₃ CH ₂	NHCOOCH ₂ CH ₃	6n	CH ₂ =CHCH ₂	N(CH ₃) ₂ (CH ₂) ₃
6e	CH ₃ CH ₂	4-CH ₃ O-C ₆ H ₄ CH ₂	6o	CH ₂ =CHCH ₂	2-furanyl-CH ₂
6f	CH ₃ CH ₂	C ₆ H ₅ CH ₂ CH ₂			

Scheme 2. Reagents and conditions: i) ROH, CH₂Cl₂, -30 to 23 °C, aq. NaOH, 20 min; ii) large excess of ROH, -10 to 23 °C, aq. NaOH, 20 min; iii) R¹NH₂, Et₂O, 35 °C, 5 min; iv) few drops of SbCl₅ or H₂SO₄, CH₂Cl₂, 35 °C, 15 min.

Antiviral activity

The urea compounds **6a–o** were examined for possible antiviral activity against the HIV-1 strain HTLV-III_B [17]. This strain of HIV-1 was propagated in H9 cells [18] at 37 °C, 5 % CO₂, using RPMI 1640 with 10 % heat-inactivated fetal calf serum (FCS) and antibiotics (growth medium). The culture supernatant was filtered (0.45 nm), aliquoted, and stored at -80 °C until use. The MT-4 cells, which were used as target cells, were incubated with virus (0.005 MOI) for 2 h, washed, and added in a proportion of 1 : 10 to uninfected cells which had been preincubated in growth

medium containing the test compounds for 6 d in parallel with virus-infected control cultures without compound added. Expression of HIV in the culture medium was quantified by the HIV antigen detection assay ELISA [19].

Compounds **6a–o** did not exhibit any significant activity at non-toxic concentrations.

It was reported in the literature that phenylethylthiazolylthiourea (PETT, LY73497) shows high potency against HIV-1. Optimization of this lead compound gave *N*-[2-(2-pyridyl)ethyl]-*N*-[2-(5-bromopyridyl)] thiourea (LY300046:HCl) (troviridine) [12], which has been selected for clinical trials (Fig. 1). Ex-

Comp.	R	R ¹	Comp.	R	R ¹
9a	CH ₂ CH ₃		11b	CH ₃ CH ₂	CH ₃
9b	CH ₂ =CHCH ₂		11c	CH ₃ CH ₂	CH ₃ CH ₂
10a	CH ₃ CH ₂		11d	CH ₂ =CHCH ₂	CH(CH ₃) ₂
10b	CH ₃ CH ₂ CH ₂		11e	CH ₂ =CHCH ₂	CH ₃
11a	CH ₃ CH ₂	CH ₂ =CHCH ₂	11f	CH ₂ =CHCH ₂	CH ₃ CH ₂

Scheme 3. Reagents and conditions: i) aq. NaOH; ii) H₂, Pd/C, CH₃OH, 30 min; iii) R¹OH, -10 °C, aq. NaOH.

Fig. 1. Selected non-nucleoside compounds in clinical use or development.

tensive structure-activity relationship (SAR) studies of the PETT compounds have been made [20, 21]. For this purpose the structure of PETT is considered as a product of four parts (Fig. 2). In part 1 of the structure, mono-, di- and trisubstitutions gave very active compounds. Both electron donating and electron withdrawing small groups like chloro, fluoro, azido and methoxy substituents showed good activity. Compounds where

Fig. 2. The four parts of the PETT compounds.

the phenyl group was replaced with 2-pyridyl, as in troviridine, gave the most active compounds in a series with different heterocycles. In part 2, the ethyl linker was optimal for activity. In part 3, the *N,N*-unsubstituted thiourea was most active. Methyl substituents on nitrogen adjacent to the phenylethyl side chain completely eliminated the activity. In part 4, the most optimal compound was achieved by replacing the thiazole with a 5-bromopyrid-2-yl. Later on, it was found that the urea-PETT compounds [15, 16] may have better toxicological and pharmacokinetic properties than the PETT compounds. Comparing these results with those for compounds **6a–o** leads us to believe that introducing the bulky group [dialkoxy(*p*-chlorophenyl)methyl] in position 2 of the tolyl substituent (part 4) is most likely the reason for elimination of the activity of compounds **6a–o**.

Experimental Section

All solvents were dried by standard methods. All experiments were carried out with exclusion of moisture. Melting points were determined with a Kofler block apparatus and are uncorrected. IR spectra were recorded with a Perkin-Elmer Model 1720 FTIR spectrometer. ¹H and ¹³C NMR spectra were determined with Varian Gemini 2000 and Bruker AC-250 FT spectrometers. The chemical shifts in ppm are expressed on the δ scale using tetramethylsilane as internal standard. Coupling constants are given in Hz. Mass spectra were recorded on an AEIMS 30 spectrometer. TLC was performed on Merck silica gel 60-F254 precoated plastic plates. Microanalyses were performed in the unit of microanalysis at Cairo University (Egypt). The biological activity was determined in the Retrovirus Laboratory, State Serum Institute, Copenhagen (Denmark).

Synthesis of 2-allyl-1-oxo-3-phenyl-1H-isoindolium hexachloroantimonate (**1b**)

A solution of SbCl₅ (1.5 g, 5 mmol) in CH₂Cl₂ (5 mL) was added dropwise with stirring at -40 °C to a solution of dichlorodiphenylmethane (1.2 g, 5 mmol) and allylisocyanate (0.42 g, 6 mmol) in CH₂Cl₂ (15 mL). The reaction mixture was warmed to 23 °C, and stirring was continued for 6 h, upon which a yellowish orange precipitate was formed. Filtration, washing with CH₂Cl₂ (5 mL) and drying under vac-

cum afforded fine yellow crystals, m. p. 184–186 °C; yield: 1.78 g (61 %). – IR (Nujol): ν = 1590 (C=C), 1757 (C=N⁺), 1811 cm^{−1} (C=O). – ¹H NMR (CD₃CN): δ = 4.74–4.76 (m, 2H, NCH₂), 5.43 (dd, 1H, J_{cis} = 10.4 Hz, 3'-H_a), 5.49 (dd, 1H, J_{trans} = 17.3 Hz, 3'-H_b), 6.01–6.14 (m, 1H, 2'-H), 7.66–8.25 (m, 9H, Ar-H). – ¹³C NMR (CD₃CN): δ = 47.2 (NCH₂), 116.9, 134.8 (CH=CH₂), 119.9, 123.1, 125.2, 128.6, 129.5, 130.1, 132.0, 136.8, 138.1, 138.4, (Ar-C), 166.0, 184.2 (C=O, C=N) ppm. – C₁₇H₁₄Cl₆NOSb (582.8): calcd. C 35.03, H 2.43, N 2.40; found C 34.5, H 2.6, N 2.2.

General procedure for the preparation of 4,4-disubstituted 1,4-dihydro-benzo[d][1,3]oxazin-2-ones 3a, b

A solution of an alcohol (7 mmol) in absolute CH₂Cl₂ (10 mL) was added to a cold (−40 °C) suspension of **2** (5 mmol) in CH₂Cl₂ (50 mL). The orange suspension disappeared immediately, and the reaction mixture became a clear yellow solution. Subsequently, a solution of NaOH (2N, 50 mL) was added. After warming to r. t., the reaction mixture was stirred for 10 min. The organic layer was separated, and the aqueous layer was repeatedly extracted with CH₂Cl₂. The combined organic extracts were dried over anhydrous Na₂SO₄. Filtration and evaporation of the solvent afforded a solid product, which could be recrystallized from appropriate solvents.

4-(2-Chlorobenzoyloxy)-4-(4-chlorophenyl)-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one (3a)

Prepared from 2-chlorobenzyl alcohol and **2** as described before. Recrystallization from CHCl₃ / *n*-pentane afforded a colorless powder; m. p. 192–193 °C; yield: 1.83 g (63 %). – IR (KBr): ν = 1611 (C=C), 1719 (C=O), 3215 cm^{−1} (NH). – ¹H NMR ([D₆]DMSO): δ = 2.18 (s, 1H, CH₃), 4.60 (s, 2H, OCH₂), 6.80–7.53 (m, 11H, Ar-H), 10.67 (s, 1H, NH) ppm. – C₂₂H₁₇Cl₂NO₃ (414.3): calcd. C 63.78, H 4.14, N 3.38; found C 63.4, H 3.8, N 3.0.

4-(4-Chlorophenyl)-4-(2-ethoxyethoxy)-6-methyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one (3b)

From 2-ethoxyethanol and **2** as described for **3a**. However, column chromatography on silica gel (EtOAc/*n*-hexane, 1:6) provided two fractions, which refer to compounds **3b** (R_f = 0.75) and **4** (R_f = 0.55).

Compound 3b: pale-yellow powder, m. p. 175–177 °C; yield: 1.57 g (62 %). – IR (KBr): ν = 1631, 1590 (C=C), 1733 (C=O), 3215 cm^{−1} (NH). – ¹H NMR ([D₆]DMSO): δ = 1.10 (t, 3H, J = 7.2 Hz, CH₃), 2.18 (s, 3H, CH₃), 3.45 (q, 2H, J = 7.3 Hz, CH₂), 3.54 (s, 4H, 2OCH₂), 6.74 (s, 1H, Ar-H), 6.87–7.53 (m, 6H, Ar-H), 10.77 (s, 1H, NH) ppm. – C₁₉H₂₀ClNO₄ (361.7): calcd. C 63.08, H 5.57, N 3.87; found C 62.7, H 5.2, N 3.5.

6,12-Bis(4-chlorophenyl)-3,9-dimethyldibenzo[b,f][1,5]diazocine (4)

Pale-yellow powder; m. p. 211 °C; yield: 0.16 g (5 %). – ¹H NMR ([D₆]DMSO): δ = 2.20 (s, 6H, 2CH₃), 6.82 (s, 2H, Ar-H), 6.92–7.64 (m, 12H, Ar-H). – ¹³C NMR ([D₆]DMSO): δ = 20.1 (2CH₃), 120.5, 125.5, 127.2, 128.6, 130.3, 130.8, 133.0, 136.1, 148.5 (Ar-C), 167.5 (2C=N) ppm. – MS (EI, 70 eV): m/z (%) = 454 (100) [M–1]⁺. – C₂₈H₂₀Cl₂N₂ (455.1): calcd. C 73.83, H 4.40, N 6.15; found C 73.5, H 4.1, N 5.7.

General procedure for the preparation of 4'-chloro-2-isocyanato-5-methylbenzophenone ketals 5a, b

A solution of a large excess of alcohol (3 mL) in CH₂Cl₂ (10 mL) was added in one portion to a cold (−10 °C) suspension of **2** (5 mmol) in CH₂Cl₂ (40 mL). After warming to r. t. in the course of 20 min, a solution of NaOH (2 g) in H₂O (50 mL) was added. Usual work-up, drying over Na₂SO₄, filtration and evaporation of the solvent afforded a yellow oil which was used without further purification.

4'-Chloro-2-isocyanato-5-methylbenzophenone-diethylketal (5a)

From **2** and ethanol (3 mL) as described before [14].

4'-Chloro-2-isocyanato-5-methylbenzophenone-diallylketal (5b)

From **2** and allyl alcohol (3 mL); yield: 1.63 g (88 %). – IR (film): ν = 1593 (C=C), 2291 cm^{−1} (NCO). – ¹H NMR (CDCl₃): δ = 2.36 (s, 3H, CH₃), 3.77 (m, 4H, 2OCH₂), 5.14 (dd, 2H, J_{cis} = 10.3 Hz, 3'-H_a), 5.36 (dd, 2H, J_{trans} = 17.0 Hz, 3'-H_b), 5.90 (m, 2H, 2'-H), 7.16–7.59 (m, 7H, Ar-H). – C₂₁H₂₀ClNO₃ (369.7): calcd. C 68.22, H 5.44, N 3.79; found C 68.5, H 5.3, N 3.5.

General procedure for the preparation of the derivatives of 1-[2-[(4-chlorophenyl)-dialkyloxymethyl]-4-methylphenyl]urea, 6a–o

A mixture of **5** (5 mmol) and a primary amine (8 mmol) in diethyl ether (50 mL) was boiled under reflux for 10 min. The solid product that formed was filtered off and recrystallized from CH₂Cl₂ / Et₂O to give fine colorless crystals.

1-[2-[(4-Chlorophenyl)diethoxymethyl]-4-methylphenyl]-urea (6a)

From ammonia and **5a** as described before, m. p. 189–191 °C; yield: 1.60 g (88 %). – IR (KBr): ν = 1592 (C=C), 1669 (C=O), 3376 cm^{−1} (NH). – ¹H NMR (CDCl₃): δ = 1.21 (t, 6H, J = 7.3 Hz, 2CH₃), 2.37 (s, 3H, CH₃), 3.23–3.34 (m, 4H, 2OCH₂), 4.32 (s, 2H, NH₂), 7.11–7.44 (m, 7H,

Ar-H), 7.71 (s, 1H, NH). – ^{13}C NMR: δ = 15.3 (2CH₃), 21.4 (CH₃), 57.6 (2OCH₂), 101.3 (OCO), 123.6, 128.2, 128.4, 128.5, 128.9, 130.1, 132.3, 133.7, 134.0, 140.1 (Ar-C), 156.1 (C=O) ppm. – C₁₉H₂₃ClN₂O₃ (362.8): calcd. C 62.89, H 6.39, N 7.72; found C 62.6, H 6.8, N 7.9.

1-[2-[(4-Chlorophenyl)diethoxymethyl]-4-methylphenyl]-3-allylurea (6b)

From allylamine and **5a**, m.p. 150–152 °C; yield: 1.45 g (72 %). – IR (KBr): ν = 1594 (C=C), 1661 (C=O), 3371 cm^{−1} (NH). – ^1H NMR (CDCl₃): δ = 1.21 (t, 6H, *J* = 7.3 Hz, 2CH₃), 2.37 (s, 3H, CH₃), 3.34 (m, 4H, 2OCH₂), 3.60 (m, 2H, NCH₂), 4.11 (t, *J* = 5.7 Hz, 1H, NH), 4.95 (dd, 1H, *J*_{cis} = 10.4 Hz, 3'-H_a), 5.02 (dd, 1H, *J*_{trans} = 17.2 Hz, 3'-H_b), 5.59 (m, 1H, 2'-H), 7.10–7.44 (m, 7H, Ar-H), 7.45 (s, 1H, NH). – ^{13}C NMR: δ = 15.3 (2CH₃), 21.4 (CH₃), 42.9 (NCH₂), 57.5 (2OCH₂), 101.1 (OCO), 115.8, 133.7 (CH₂=CH), 124.1, 128.4, 128.6, 128.9, 130.2, 132.6, 133.4, 134.1, 135.3, 140.2 (Ar-C), 155.3 (C=O) ppm. – C₂₂H₂₇ClN₂O₃ (402.9): calcd. C 65.58, H 6.75, N 6.95; found C 65.9, H 7.1, N 7.2.

1-[2-[(4-Chlorophenyl)diethoxymethyl]-4-methylphenyl]-3-(1-phenylethyl)urea (6c)

From 1-phenylethylamine and **5a**, m.p. 199–201 °C; yield: 1.66 g (71 %). – IR (KBr): ν = 1593 (C=C), 1661 (C=O), 3370 cm^{−1} (NH). – ^1H NMR (CDCl₃): δ = 1.15–1.25 (m, 6H, 2CH₃), 1.29 (d, *J* = 6.8 Hz, 3H, CH₃), 2.36 (s, 3H, CH₃), 3.19–3.34 (m, 4H, 2OCH₂), 4.30 (m, 1H, CH), 4.77 (s, 1H, NH), 7.07–7.43 (m, 12H, Ar-H), 7.72 (s, 1H, NH). – ^{13}C NMR: δ = 15.4 (2CH₃), 21.4 (CH₃), 22.5 (CH₃), 49.6 (NCH), 57.6 (2OCH₂), 101.1 (OCO), 123.8, 126.3, 127.4, 128.4, 128.6, 128.7, 128.9, 130.1, 132.2, 133.1, 133.8, 134.1, 140.3 (Ar-C), 154.5 (C=O) ppm. – C₂₇H₃₁ClN₂O₃ (466.9): calcd. C 69.45, H 6.66, N 6.00; found C 69.8, H 6.9, N 6.4.

Ethyl-2-[2-[(4-chlorophenyl)diethoxymethyl]-4-methylphenylamino]carbonylhydrazine carboxylate (6d)

From ethyl carbamate and **5a**, m.p. 203–205 °C; yield: 1.51 g (67 %). – IR (KBr): ν = 1595 (C=C), 1702 (C=O), 3352 cm^{−1} (NH). – ^1H NMR (CDCl₃): δ = 1.18 (t, 6H, *J* = 7.3 Hz, 2CH₃), 1.30 (t, *J* = 7.2 Hz, 3H, CH₃), 2.37 (s, 3H, CH₃), 3.23–3.34 (m, 4H, 2OCH₂), 4.22 (q, *J* = 6.8 Hz, 2H, OCH₂), 6.40, 6.50 (2s, 2H, 2NH), 7.10–7.37 (m, 7H, Ar-H), 8.53 (s, 1H, NH). – ^{13}C NMR: δ = 14.8 (CH₃), 15.2 (2CH₃), 21.4 (CH₃), 57.6 (2OCH₂), 62.9 (OCH₂), 101.3 (OCO), 128.2, 128.3, 128.7, 128.8, 129.7, 130.0, 132.5, 133.1, 134.2, 139.7 (Ar-C), 155.6, 156.9 (2C=O) ppm. – C₂₂H₂₈ClN₃O₅ (449.9): calcd. C 58.73, H 6.27, N 9.34; found C 59.1, H 6.6, N 9.7.

1-[2-[(4-Chlorophenyl)diethoxymethyl]-4-methylphenyl]-3-(4-methoxybenzyl)urea (6e)

From 4-methoxybenzylamine and **5a**, m.p. 190–192 °C; yield: 1.71 g (71 %). – IR (KBr): ν = 1593 (C=C), 1667 (C=O), 3368 cm^{−1} (NH). – ^1H NMR (CDCl₃): δ = 1.19 (t, 6H, *J* = 7.1 Hz, 2CH₃), 2.30 (s, 3H, CH₃), 3.18–3.32 (m, 4H, 2OCH₂), 3.73 (s, 3H, OCH₃), 4.08 (d, *J* = 6.1 Hz, 2H, NCH₂), 6.86–7.63 (m, 11H, Ar-H), 7.71 (s, 1H, NH), 8.31 (s, 1H, NH). – ^{13}C NMR: δ = 15.2 (2CH₃), 21.6 (CH₃), 42.9 (NCH₂), 55.9 (OCH₃), 57.7 (OCH₂), 101.3 (OCO), 114.5, 123.4, 128.0, 128.6, 129.0, 129.2, 129.5, 129.8, 130.3, 131.1, 133.2, 135.0, 140.8, 159.0 (Ar-C), 155.3 (C=O) ppm. – C₂₇H₃₁ClN₂O₄ (483.0): calcd. C 67.14, H 6.47, N 5.80; found C 67.5, H 6.8, N 6.1.

1-[2-[(4-Chlorophenyl)diethoxymethyl]-4-methylphenyl]-3-(2-phenylethyl)urea (6f)

From 2-phenylethylamine and **5a**, m.p. 195–197 °C; yield: 1.80 g (77 %). – IR (KBr): ν = 1593 (C=C), 1655 (C=O), 3374 cm^{−1} (NH). – ^1H NMR (CDCl₃): δ = 1.80 (t, 6H, *J* = 7.3 Hz, 2CH₃), 2.37 (s, 3H, CH₃), 2.61 (m, 2H, CH₂), 3.19–3.31 (m, 6H, 3CH₂), 4.08 (bs, 1H, NH), 7.01–7.38 (m, 12H, Ar-H), 7.70 (s, 1H, NH). – ^{13}C NMR: δ = 15.4 (2CH₃), 21.4 (CH₃), 36.4 (CH₂), 41.7 (NCH₂), 57.6 (2OCH₂), 101.2 (OCO), 123.8, 126.7, 128.3, 128.4, 128.6, 128.8, 128.9, 129.1, 130.1, 132.3, 133.2, 133.8, 134.0, 140.1 (Ar-C), 155.3 (C=O) ppm. – C₂₇H₃₁ClN₂O₃ (466.9): calcd. C 69.45, H 6.66, N 6.00; found C 69.7, H 6.8, N 6.2.

1-[2-[(4-Chlorophenyl)diethoxymethyl]-4-methylphenyl]-3-furan-2-yl-methylurea (6g)

From 2-furanylmethylamine and **5a**, m.p. 158–160 °C; yield: 1.62 g (73 %). – IR (KBr): ν = 1594 (C=C), 1661 (C=O), 3367 cm^{−1} (NH). – ^1H NMR (CDCl₃): δ = 1.91 (t, 6H, *J* = 7.3 Hz, 2CH₃), 2.36 (s, 3H, CH₃), 3.19–3.29 (m, 4H, 2OCH₂), 4.18 (d, *J* = 5.9 Hz, 2H, NCH₂), 4.40 (t, 1H, *J* = 5.5 Hz, NH), 6.04 (d, *J* = 2.5 Hz, 1H, furanyl), 6.30 (m, 1H, furanyl), 7.08–7.47 (m, 7H, Ar-H), 7.72 (d, *J* = 1.8 Hz, 1H, furanyl). – ^{13}C NMR: δ = 15.4 (2CH₃), 21.4 (CH₃), 37.5 (NCH₂), 57.6 (2OCH₂), 101.2 (OCO), 107.2, 110.7, 142.2, 152.3 (furanyl-C), 123.8, 128.4, 128.5, 128.9, 130.2, 132.3, 133.3, 133.7, 134.0, 140.1 (Ar-C), 155.0 (C=O) ppm. – C₂₄H₂₇ClN₂O₄ (442.9): calcd. C 65.08, H 6.14, N 6.32; found C 64.7, H 5.9, N 5.9.

1-[2-[(4-Chlorophenyl)diethoxymethyl]-4-methylphenyl]-3-(4-ethoxyphenyl)urea (6h)

From 4-ethoxyaniline and **5a**, m.p. 199–201 °C; yield: 1.93 g (80 %). – IR (KBr): ν = 1594 (C=C), 1667 (C=O), 3371 cm^{−1} (NH). – ^1H NMR (CDCl₃): δ = 1.11 (t, 6H, *J* = 7.2 Hz, 2CH₃), 1.43 (t, 3H, *J* = 7.1 Hz, CH₃), 2.37 (s, 3H,

CH₃), 3.13–3.25 (m, 4H, 2OCH₂), 4.06 (q, 2H, *J* = 7.1 Hz, OCH₂), 6.10 (s, 1H, NH), 6.86–7.71 (m, 11H, Ar-H). – ¹³C NMR: δ = 15.3 (2CH₃), 21.4 (CH₃), 57.4 (2OCH₂), 64.1 (OCH₂), 101.0 (OCO), 115.4, 123.8, 126.3, 128.2, 128.7, 129.0, 130.0, 130.1, 131.6, 133.0, 133.5, 133.9, 139.6, 154.2 (Ar-C), 157.2 (C=O) ppm. – C₂₇H₃₁ClN₂O₄ (483.0): calcd. C 67.14, H 6.47, N 5.80; found C 67.4, H 6.7, N 6.2.

1-[2-[(4-Chlorophenyl)diallyloxymethyl]-4-methylphenyl]-3-(4-methoxyphenyl)urea (6i)

From 4-methoxyaniline and **5a**, m. p. 150–152 °C; yield: 1.88 g (80 %). – IR (KBr): ν = 1595 (C=C), 1667 (C=O), 3370 cm⁻¹ (NH). – ¹H NMR (CDCl₃): δ = 1.17 (t, 6H, *J* = 7.2 Hz, 2CH₃), 2.37 (s, 3H, CH₃), 3.13–3.25 (m, 4H, 2OCH₂), 3.83 (s, 3H, OCH₃), 5.96 (s, 1H, NH), 6.86–7.25 (m, 11H, Ar-H), 7.41 (s, 1H, NH). – ¹³C NMR: δ = 15.3 (2CH₃), 21.4 (CH₃), 55.9 (OCH₃), 57.4 (OCH₂), 101.0 (OCO), 114.8, 123.8, 126.2, 128.2, 128.7, 130.0, 130.3, 131.6, 133.0, 133.5, 133.9, 139.7, 154.1 (Ar-C), 157.8 (C=O) ppm. – C₂₆H₂₉ClN₂O₄ (469.0): calcd. C 66.59, H 6.23, N 5.97; found C 66.9, H 6.5, N 6.3.

1-[2-[(4-Chlorophenyl)diallyloxymethyl]-4-methylphenyl]-urea (6j)

From ammonia and **5b**, m. p. 155–156 °C; yield: 1.61 g (83 %). – IR (KBr): ν = 1591 (C=C), 1669 (C=O), 3380 cm⁻¹ (NH). – ¹H NMR (CDCl₃): δ = 2.37 (s, 3H, CH₃), 3.79 (m, 4H, 2OCH₂), 4.50 (s, 2H, NH₂), 5.17 (dd, 2H, *J*_{cis} = 10.5 Hz, 3'-H_a), 5.32 (dd, 2H, *J*_{trans} = 17.1 Hz, 3'-H_b), 5.92 (m, 2H, 2'-H), 7.12–7.51 (m, 7H, Ar-H), 7.75 (s, 1H, NH). – ¹³C NMR: δ = 21.5 (CH₃), 63.3 (2OCH₂), 101.7 (OCO), 117.0, 133.7, (2CH₂=CH), 117.1, 124.0, 128.5, 128.6, 128.9, 130.5, 131.1, 134.3, 134.4, 139.5 (Ar-C), 156.0 (C=O) ppm. – C₂₁H₂₃ClN₂O₃ (386.9): calcd. C 65.20, H 5.99, N 7.24; found C 64.9, H 5.6, N 6.9.

1-[2-[(4-Chlorophenyl)diallyloxymethyl]-4-methylphenyl]-3-allylurea (6k)

From allylamine and **5b**, m. p. 197–199 °C; yield: 1.64 g (77 %). – IR (KBr): ν = 1563 (C=C), 1642 (C=O), 3360 cm⁻¹ (NH). – ¹H NMR (CDCl₃): δ = 2.38 (s, 3H, CH₃), 3.58–3.62 (m, 2H, NCH₂), 3.82 (m, 4H, 2OCH₂), 4.13 (bs, 1H, NH), 4.95 (dd, 2H, *J*_{cis} = 9.5 Hz, 3'-H_a), 5.04 (dd, 2H, *J*_{trans} = 16.7 Hz, 3'-H_b), 5.17 (dd, 1H, *J*_{cis} = 10.4 Hz, 3''-H_a), 5.50 (dd, 1H, *J*_{trans} = 16.7 Hz, 3''-H_b), 5.62 (m, 2H, 2'-H), 5.89 (m, 1H, 2''-H), 7.07–7.49 (m, 7H, Ar-H), 7.77 (s, 1H, NH). – ¹³C NMR: δ = 21.5 (CH₃), 42.9 (NCH₂), 63.3 (2OCH₂), 101.5 (OCO), 115.8, 117.1, 133.7, 134.3 (3CH₂=CH), 124.3, 128.5, 128.6, 128.8, 130.4, 131.9, 133.5, 134.4, 135.3, 139.5 (Ar-C), 155.1 (C=O) ppm. – C₂₄H₂₇ClN₂O₃ (426.9): calcd. C 67.52, H 6.37, N 6.56; found C 67.2, H 6.0, N 6.3.

1-[2-[(4-Chlorophenyl)diallyloxymethyl]-4-methylphenyl]-3-benzylurea (6l)

From benzylamine and **5b**, m. p. 193–194 °C; yield: 1.88 g (79 %). – IR (KBr): ν = 1592 (C=C), 1657 (C=O), 3369 cm⁻¹ (NH). – ¹H NMR (CDCl₃): δ = 2.36 (s, 3H, CH₃), 3.78 (m, 4H, 2OCH₂), 4.20 (d, 2H, *J* = 5.7 Hz, NCH₂), 4.38 (s, 1H, NH), 5.15 (dd, 2H, *J*_{cis} = 10.9 Hz, 3'-H_a), 5.30 (dd, 2H, *J*_{trans} = 17.6 Hz, 3'-H_b), 5.82 (m, 2H, 2'-H), 7.07–7.54 (m, 12H, Ar-H). – ¹³C NMR: δ = 21.2 (CH₃), 44.3 (NCH₂), 63.1 (2OCH₂), 101.3 (OCO), 116.9, 134.1 (2CH₂=CH), 123.7, 127.4, 127.5, 128.3, 128.4, 128.6, 128.7, 130.3, 131.3, 133.1, 133.5, 134.2, 139.3 (Ar-C), 154.9 (C=O) ppm. – C₂₈H₂₉ClN₂O₃ (477.0): calcd. C 70.50, H 6.13, N 5.87; found C 70.7, H 6.5, N 6.1.

1-[2-[(4-Chlorophenyl)diallyloxymethyl]-4-methylphenyl]-3-(4-methoxyphenyl)urea (6m)

From 4-methoxyaniline and **5b**, m. p. 206–208 °C; yield: 1.90 g (77 %). – IR (KBr): ν = 1594 (C=C), 1665 (C=O), 3381 cm⁻¹ (NH). – ¹H NMR (CDCl₃): δ = 2.37 (s, 3H, CH₃), 3.71–3.77 (m, 4H, 2OCH₂), 3.83 (s, 3H, OCH₃), 5.14 (dd, 2H, *J*_{cis} = 9.2 Hz, 3'-H_a), 5.78 (dd, 2H, *J*_{trans} = 15.5 Hz, 3'-H_b), 5.84 (m, 2H, 2'-H), 6.86–7.38 (m, 11H, Ar-H), 7.74 (s, 1H, NH). – ¹³C NMR: δ = 21.5 (CH₃), 55.8 (OCH₃), 63.2 (2OCH₂), 101.3 (OCO), 116.9, 134.7 (2CH₂=CH), 114.9, 123.8, 126.1, 128.4, 128.6, 130.2, 130.3, 130.8, 133.1, 133.5, 134.3, 139.0, 157.7 (Ar-C), 154.0 (C=O) ppm. – C₂₈H₂₉ClN₂O₄ (493.0): calcd. C 68.22, H 5.93, N 5.68; found C 68.6, H 6.3, N 5.9.

1-[2-[(4-Chlorophenyl)diallyloxymethyl]-4-methylphenyl]-3-(3-dimethylaminopropyl)urea (6n)

From 3-(dimethylamino)propylamine and **5b**, m. p. 148–150 °C; yield: (1.77 g (75 %)). – IR (KBr): ν = 1570 (C=C), 1640 (C=O), 3348 cm⁻¹ (NH). – ¹H NMR (CDCl₃): δ = 1.41–1.50 (m, 2H, CH₂), 2.07 (s, 6H, N(CH₃)₂), 2.10–2.24 (m, 2H, NCH₂), 2.37 (s, 3H, CH₃), 3.02–3.08 (m, 2H, NCH₂), 3.79–3.85 (m, 4H, 2OCH₂), 5.16 (dd, 2H, *J*_{cis} = 9.6 Hz, 3'-H_a), 5.35 (dd, 2H, *J*_{trans} = 17.1 Hz, 3'-H_b), 5.66 (t, 1H, *J* = 4.2 Hz, NH), 5.84–5.97 (m, 2H, 2'-H), 7.10–7.45 (m, 7H, Ar-H), 7.77 (s, 1H, NH). – ¹³C NMR: δ = 21.4 (CH₃), 26.3 (CH₂), 40.7 (NCH₂), 45.7 (N(CH₃)₂), 59.1 (NCH₂), 63.2 (2OCH₂), 101.3 (OCO), 116.9, 134.3 (2CH₂=CH), 124.2, 128.4, 128.6, 128.7, 130.3, 131.6, 133.0, 134.1, 134.2, 139.5 (Ar-C), 155.6 (C=O) ppm. – C₂₆H₃₄ClN₃O₃ (472.0): calcd. C 66.16, H 7.26, N 8.90; found C 65.9, H 6.9, N 8.6.

1-[2-[(4-Chlorophenyl)diallyloxymethyl]-4-methylphenyl]-3-furan-2-yl-methylurea (6o)

From 2-furanylmethylamine and **5b**, m. p. 166–168 °C; yield: 1.84 g (79 %). – IR (KBr): ν = 1594 (C=C), 1665

(C=O), 3361 cm^{-1} (NH). – ^1H NMR (CDCl_3): δ = 2.37 (s, 3H, CH_3), 3.80 (m, 4H, 2OCH_2), 4.17 (m, 2H, NCH_2), 4.40 (bs, 1H, NH), 5.18 (dd, 2H, J_{cis} = 10.0 Hz, $3'\text{-H}_a$), 5.35 (dd, 2H, J_{trans} = 17.0 Hz, $3'\text{-H}_b$), 5.91 (m, 2H, $2'\text{-H}$), 6.05 (d, J = 3.1 Hz, 1H, furanyl), 6.30 (d, J = 2.0 Hz, 1H, furanyl), 7.11–7.51 (m, 7H, Ar-H), 7.74 (s, 1H, NH). – ^{13}C NMR: δ = 21.5 (CH_3), 37.6 (NCH_2), 63.3 (2OCH_2), 101.6 (OCO), 107.2, 107.3, 142.2, 152.3 (furanyl-C), 117.1, 134.3 ($2\text{CH}_2=\text{CH}$), 124.0, 128.6, 130.5, 131.6, 133.5, 133.7, 134.4, 139.5 (Ar-C), 155.9 (C=O) ppm. – $\text{C}_{26}\text{H}_{27}\text{ClN}_2\text{O}_4$ (467.0): calcd. C 66.88, H 5.83, N 6.00; found C 66.5, H 5.5, N 6.4.

4-(4-Chlorophenyl)-6-methyl-1H-quinazolin-2-one (8)

A solution of conc. H_2SO_4 or SbCl_5 (3 drops) in 5 mL of CH_2Cl_2 was added to a solution of **6** (5 mmol) in CH_2Cl_2 (15 mL). Boiling the reaction mixture under reflux for 10 min with stirring afforded a yellow precipitate which was recrystallized from ethanol to give fine yellow crystals, m. p. 205–207 $^\circ\text{C}$; yield: 0.96 g (71 %). – ^1H NMR ($[\text{D}_6]\text{DMSO}$): δ = 2.32 (s, 3H, CH_3), 7.37–7.75 (m, 7H, Ar-H), 9.17 (bs, 1H, NH). – ^{13}C NMR: δ = 21.4 (CH_3), 114.8, 116.9, 129.1, 129.7, 132.4, 133.2, 133.9, 137.3, 140.3, 143.4 (Ar-C), 152.7, 174.1 (C=O, C=N) ppm. – $\text{C}_{15}\text{H}_{11}\text{ClN}_2\text{O}$ (270.7): calcd. C 66.55, H 4.07, N 10.34; found C 66.9, H 4.4, N 10.7.

General procedure for the preparation of **9a, b**

An aqueous solution of NaOH (2N, 50 mL) was added to a suspension of **1** (5 mmol) in CH_2Cl_2 (20 mL) at 0 $^\circ\text{C}$ with stirring for 20 min. The organic layer was separated, and the aqueous layer was repeatedly extracted with CH_2Cl_2 . The combined extract was dried over anhydrous Na_2SO_4 . Evaporation of the solvent afforded a colorless powder, which can be recrystallized from CH_2Cl_2 /*n*-pentane to give fine colorless crystals.

2-Ethyl-3-hydroxy-3-phenyl-2,3-dihydro-isoindol-1-one (**9a**)

From **1a** as described before, m. p. 157 $^\circ\text{C}$; yield: 1.15 g (91 %). – IR (KBr): ν = 1620 (C=C), 1687 (C=O), 3325 cm^{-1} (OH). – ^1H NMR (CDCl_3): δ = 0.94 (t, 3H, J = 7.3 Hz, CH_3), 2.97–3.09, 3.33–3.45 (2m, 2H, NCH_2), 4.23 (s, 1H, OH), 7.23–7.58 (m, 9H, Ar-H). – ^{13}C NMR: δ = 14.4 (CH_3), 34.5 (NCH_2), 91.7 (C-3), 122.9, 123.4, 126.6, 128.6, 128.7, 129.7, 130.9, 132.8, 139.1, 149.4 (Ar-C), 168.0 (C=O) ppm. – $\text{C}_{16}\text{H}_{15}\text{NO}_2$ (253.3): calcd. C 75.87, H 5.97, N 5.53; found C 75.5, H 5.6, N 5.3.

2-Allyl-3-hydroxy-3-phenyl-2,3-dihydro-isoindol-1-one (**9b**)

From **1b** as described before, m. p. 142 $^\circ\text{C}$ (lit. [22]: 145 $^\circ\text{C}$); yield: 1.11 g (84 %). – IR (KBr): ν = 1558 (C=C), 1687 (C=O), 3334 cm^{-1} (OH). – ^1H NMR (CDCl_3): δ =

3.49–4.00 (m, 2H, NCH_2), 4.45 (s, 1H, OH), 4.86–4.99 (m, 2H, $3'\text{-H}_a$, $3'\text{-H}_b$), 5.52–5.65 (m, 1H, $2'\text{-H}$), 7.22–7.79 (m, 9H, Ar-H). – ^{13}C NMR: δ = 42.1 (NCH_2), 91.7 (C-3), 117.5, 133.8 ($\text{CH}_2=\text{CH}$), 123.1, 123.5, 126.7, 128.6, 128.7, 129.6, 130.6, 132.9, 139.1, 149.4 (Ar-C), 168.0 (C=O) ppm. – $\text{C}_{17}\text{H}_{15}\text{NO}_2$ (265.1): calcd. C 76.95, H 5.66, N 5.28; found C 76.6, H 5.3, N 4.9.

General procedure for the preparation of **10a, b**

A stream of hydrogen gas was passed through a mixture of **9** (2 mmol) and Pd/C (0.16 g) in absolute methanol (20 mL) with stirring at r. t. for 30 min. Filtration and evaporation of the solvent afforded a colorless powder.

2-Ethyl-3-phenyl-2,3-dihydro-isoindol-1-one (**10a**)

From **9a** as described before, m. p. 100 $^\circ\text{C}$ (lit. [23]: 98 $^\circ\text{C}$); yield: 0.44 g (93 %). – IR (KBr): ν = 1612 (C=C), 1674 cm^{-1} (C=O). – ^1H NMR (CDCl_3): δ = 1.12 (t, 3H, J = 7.2 Hz, CH_3), 2.93–3.00, 3.93–4.00 (2m, 2H, NCH_2), 5.46 (s, 1H, CH), 7.13–7.89 (m, 9H, Ar-H). – ^{13}C NMR: δ = 13.5 (CH_3), 34.9 (NCH_2), 63.9 (C-3), 123.0, 123.3, 127.5, 128.2, 128.6, 129.1, 131.6, 131.8, 137.1, 146.2 (Ar-C), 168.3 (C=O) ppm. – $\text{C}_{16}\text{H}_{15}\text{NO}$ (237.1): calcd. C 80.99, H 6.33, N 5.90; found C 81.3, H 6.6, N 6.2.

3-Phenyl-2-*n*-propyl-2,3-dihydro-isoindol-1-one (**10b**)

From **9b** as described before, m. p. 95 $^\circ\text{C}$ (lit. [23]: 93 $^\circ\text{C}$); yield: 0.43 g (85 %). – IR (KBr): ν = 1611 (C=C), 1672 cm^{-1} (C=O). – ^1H NMR (CDCl_3): δ = 0.70–0.78 (m, 3H, CH_3), 1.36–1.53 (m, 2H, CH_2), 2.70–2.88, 3.71–3.87 (2m, 2H, NCH_2), 5.35 (s, 1H, CH), 7.01–7.79 (m, 9H, Ar-H). – ^{13}C NMR: δ = 11.2 (CH_3), 21.4 (CH_2), 41.7 (NCH_2), 64.3 (C-3), 122.9, 123.3, 127.4, 128.1, 128.5, 128.9, 131.5, 131.6, 137.0, 146.1 (Ar-C), 168.5 (C=O) ppm. – $\text{C}_{17}\text{H}_{17}\text{NO}$ (251.0): calcd. C 81.28, H 6.78, N 5.58; found C 81.6, H 7.1, N 5.8.

General procedure for the preparation of **11a–f**

Excess alcohol (2 mL) was added to a cold (–10 $^\circ\text{C}$) suspension of **1** (5 mmol) in CH_2Cl_2 (20 mL) with stirring for 20 min. Aqueous NaOH (2N, 50 mL) was added to the reaction mixture. Repeated extraction of the organic layer with CH_2Cl_2 , filtration, drying over Na_2SO_4 and evaporation of the solvent afforded fine colorless crystals.

3-Allyloxy-2-ethyl-3-phenyl-2,3-dihydro-isoindol-1-one (**11a**)

From **1a** and allyl alcohol as describe before, m. p. 132 $^\circ\text{C}$; yield: 1.36 g (93 %). – IR (KBr): ν = 1582 (C=C), 1697 cm^{-1} (C=O). – ^1H NMR (CDCl_3): δ = 1.05 (t, 3H, J = 7.2 Hz,

CH₃), 3.07–3.22, 3.66–3.76 (2m, 2H, NCH₂), 3.42–3.54 (m, 2H, OCH₂), 5.12–5.36 (m, 2H, 3'-H_a, 3'-H_b), 5.80 (m, 1H, 2'-H), 7.12–7.91 (m, 9H, Ar-H). – ¹³C NMR: δ = 13.2 (CH₃), 34.0 (NCH₂), 63.2 (OCH₂), 94.9 (C-3), 116.0, 133.4 (CH₂=CH), 122.7, 122.9, 126.0, 127.9, 128.1, 129.3, 129.7, 132.0, 133.4, 138.6, 145.2 (Ar-C), 167.7 (C=O) ppm. – C₁₉H₁₉NO₂ (293.4): calcd. C 77.79, H 6.53, N 4.77; found C 77.4, H 6.2, N 4.8.

2-Ethyl-3-methoxy-3-phenyl-2,3-dihydro-isoindol-1-one (11b)

From **1a** and methyl alcohol, m.p. 112 °C; yield: 1.26 g (94 %). – IR (KBr): ν = 1612 (C=C), 1701 cm⁻¹ (C=O). – ¹H NMR (CDCl₃): δ = 0.92 (t, 3H, *J* = 7.2 Hz, CH₃), 3.87 (s, 3H, OCH₃), 3.01–3.08, 3.29–3.36 (2m, 2H, NCH₂), 7.00–7.77 (m, 9H, Ar-H). – ¹³C NMR: δ = 12.3 (CH₃), 33.2 (NCH₂), 49.3 (OCH₃), 94.5 (C-3), 121.9, 122.2, 125.2, 127.3, 128.5, 131.2, 131.3, 137.8, 144.2 (Ar-C), 167.5 (C=O) ppm. – C₁₇H₁₇NO₂ (267.3): calcd. C 76.38, H 6.41, N 5.24; found C 76.1, H 6.1, N 4.9.

3-Ethoxy-2-ethyl-3-phenyl-2,3-dihydro-isoindol-1-one (11c)

From **1a** and ethyl alcohol, m.p. 90–91 °C; yield: 1.29 g (92 %). – IR (KBr): ν = 1611 (C=C), 1702 cm⁻¹ (C=O). – ¹H NMR (CDCl₃): δ = 1.05 (t, 3H, *J* = 7.2 Hz, CH₃), 1.20 (t, 3H, *J* = 7.0 Hz, CH₃), 2.94–3.00, 3.39–3.67 (2m, 2H, NCH₂), 3.13–3.25 (2m, 2H, OCH₂), 7.11–7.88 (m, 9H, Ar-H). – ¹³C NMR: δ = 13.5, 14.9 (2CH₃), 34.2 (NCH₂), 58.1.3 (OCH₂), 94.9 (C-3), 123.1, 126.3, 127.3, 128.3, 128.4, 129.4, 132.2, 139.1, 145.0 (Ar-C), 168.0 (C=O) ppm. – C₁₈H₁₉NO₂ (281.4): calcd. C 76.84, H 6.81, N 4.98; found C 76.5, H 6.6, N 4.6.

2-Allyl-3-isopropoxy-3-phenyl-2,3-dihydro-isoindol-1-one (11d)

From **1b** and isopropyl alcohol, m.p. 150 °C; yield: 1.40 g (91 %). – IR (KBr): ν = 1612 (C=C), 1703 cm⁻¹ (C=O). – ¹H NMR (CDCl₃): δ = 0.91 (d, 3H, *J* = 6.1 Hz, CH₃), 1.41 (d, 3H, *J* = 6.1 Hz, CH₃), 3.37–3.48 (m, 1H, OCH),

3.51–3.60, 3.90–3.99 (2m, 2H, NCH₂), 4.88–4.93 (m, 2H, 3'-H_a, 3'-H_b), 5.53–5.69 (m, 1H, 2'-H), 7.18–7.81 (m, 9H, Ar-H). – ¹³C NMR: δ = 23.8, 23.9 (2CH₃), 41.9 (NCH₂), 66.1 (OCH), 91.3 (C-3), 117.4, 133.5 (CH₂=CH), 122.8, 123.2, 123.8, 126.7, 128.4, 129.4, 130.4, 132.2, 138.7, 146.4 (Ar-C), 168.1 (C=O) ppm. – C₂₀H₂₁NO₂ (307.4): calcd. C 78.15, H 6.89, N 4.56; found C 77.9, H 6.6, N 4.3.

2-Allyl-3-methoxy-3-phenyl-2,3-dihydro-isoindol-1-one (11e)

From **1b** and methyl alcohol, m.p. 114 °C; yield: 1.30 g (93 %). – IR (KBr): ν = 1614 (C=C), 1687 cm⁻¹ (C=O). – ¹H NMR (CDCl₃): δ = 2.98 (s, 3H, OCH₃), 3.61–3.69, 3.96–4.06 (2m, 2H, NCH₂), 4.97–5.12 (m, 2H, 3'-H_a, 3'-H_b), 5.67–5.80 (m, 1H, 2'-H), 7.13–7.89 (m, 9H, Ar-H). – ¹³C NMR: δ = 41.0 (NCH₂), 49.4 (OCH₃), 94.4 (C-3), 116.8, 131.6 (CH₂=CH), 121.9, 122.3, 125.3, 127.3, 127.4, 128.6, 131.4, 131.6, 137.6, 144.2 (Ar-C), 166.9 (C=O) ppm. – C₁₈H₁₇NO₂ (279.4): calcd. C 77.37, H 6.09, N 5.00; found C 77.5, H 5.7, N 4.6.

2-Allyl-3-ethoxy-3-phenyl-2,3-dihydro-isoindol-1-one (11f)

From **1b** and ethyl alcohol, m.p. 134 °C; yield: 1.33 g (91 %). – IR (KBr): ν = 1611 (C=C), 1701 cm⁻¹ (C=O). – ¹H NMR (CDCl₃): δ = 1.18 (t, 3H, *J* = 7.1 Hz, CH₃), 2.93–2.99 (m, 2H, OCH₂), 3.58–3.69, 3.99–4.09 (2m, 2H, NCH₂), 5.00–5.13 (m, 2H, 3'-H_a, 3'-H_b), 5.69–5.85 (m, 1H, 2'-H), 7.14–7.90 (m, 9H, Ar-H). – ¹³C NMR: δ = 14.5 (CH₃), 41.9 (NCH₂), 58.0 (OCH₂), 94.4 (C-3), 117.4, 132.8 (CH₂=CH), 122.8, 123.1, 126.1, 128.1, 128.2, 129.3, 132.1, 138.7, 145.6 (Ar-C), 167.7 (C=O) ppm. – C₁₉H₁₉NO₂ (293.4): calcd. C 77.79, H 6.33, N 4.77; found C 77.4, H 6.5, N 4.3.

Acknowledgements

The Deutsche Forschungsgemeinschaft (DFG) is gratefully acknowledged for partial support and Prof. Dr. Claus Nielsen for the determination of the biological activity against HIV.

- [1] V.J. Merluzzi, K.D. Hargave, M. Labadia, K. Grozinger, M. Skoog, J.C. Wu, C.K. Shih, K. Eckner, S. Hattox, J. Adams, A.S. Rosenthal, R. Faanes, R.J. Eckner, R.A. Koup, J.L. Sullivan, *Science* **1990**, 250, 1411.
- [2] K.D. Hargave, J.R. Proudfoot, K.G. Grozinger, E. Cullen, S.R. Kapadia, U.R. Patel, V.U. Fuchs, S.C. Mauldin, J.W. Vitous, D.W. Neil, J.M. Rose, G.C. Chow, M.T. Skoog, J.C. Wu, G. Schmidt, W.W. Engel, W.G. Eberlein, T.D. Saboe, S.J. Campell, A.S. Rosenthal, J. Adam, *J. Med. Chem.* **1991**, 34, 2231.
- [3] D.L. Romero, R.A. Morge, M.J. Genin, C. Biles, M. Busso, L. Resnick, I.W. Althaus, F. Reusser, R.C. Thomas, W.G. Tarpley, *J. Med. Chem.* **1993**, 36, 1505.
- [4] D.L. Romero, R.A. Morge, C. Biles, N. Berrios-Pena, P.D. May, J.R. Palmer, P.D. Jonson, H.W. Smith, M. Busso, C.K. Tan, R.L. Voorman, F. Reusser, I.W. Althaus, K.M. Downey, A.G. So, L. Resnick, W.G. Tarpley, P.A. Aristoff, *J. Med. Chem.* **1994**, 37, 999.
- [5] S.D. Young, S.F. Britcher, L.O. Tran, L.S. Payne, W.C. Lumma, T.A. Lyle, J.R. Huff, P.S. Anderson, D.B. Olsen, S.S. Carroll, D.J. Pettibone, J.A. O'Brien,

- R. G. Ball, S. K. Balani, J. H. Lin, I.-W. Chen, W. A. Scheif, V. V. Sardana, W. J. Long, V. W. Byrens, E. A. Emini, *Antimicrob. Agents Chemother.* **1995**, 39, 2602.
- [6] H. J. Stellbrink, *Eur. J. Med. Res.* **2007**, 12, 483.
- [7] K. Das, A. D. Clark, P. J. Lewi, J. Heeres, M. R. De Jonge, L. M. Koymans, H. M. Vinkers, F. Daeyaert, D. W. Ludovici, M. J. Kukla, B. De Corte, R. W. Kavash, C. Y. Ho, H. Ye, M. A. Lichtenstein, K. Andries, R. Pauwels, M. P. De Be'thune, P. L. Boyer, P. Clark, S. H. Hughes, P. A. Janssen, E. Arnold, *J. Med. Chem.* **2004**, 47, 2550.
- [8] M. M. Baba, S. Shigeta, S. Yuasa, H. Takashima, K. Sekiya, M. Ubasawa, H. Tanaka, T. Miyasaka, R. T. Walker, E. De Clercq, *Antimicrob. Agents Chemother.* **1994**, 38, 688.
- [9] R. Pauwels, K. Andries, Z. Debyser, M. J. Kukla, D. Schols, H. J. Breslin, R. Woestenborghs, J. Desmyter, M. A. C. Janssen, E. De Clercq, P. A. J. Janssen, *Antimicrob. Agents Chemother.* **1994**, 38, 2863.
- [10] A. A. Hamed, *Z. Naturforsch.* **2004**, 56b, 589.
- [11] A. A. Hamed, *J. Chem. Res. (S)* **2005**, 54.
- [12] C. Ahgren, K. Backro, F. W. Bell, A. S. Cantrell, M. Clemens, J. M. Colacino, J. B. Deeter, J. A. Engelhardt, M. Högberg, S. R. Jaskunas, N. G. Johansson, C. L. Jordan, J. S. Kasher, M. D. Kinnick, P. Lind, C. Lopez, J. M. Morin, M. A. Muesing, R. Noreen, B. Öberg, C. J. Paget, J. A. Palkowitz, C. A. Parrish, P. Pranc, M. K. Rippey, C. Rydergard, C. Sahlberg, S. Swanson, R. J. Ternansky, T. Unge, R. T. Vasileff, L. Vrang, S. J. West, H. Zhang, X. X. Zhou, *Antimicrob. Agents Chemother.* **1995**, 39, 1329.
- [13] G. Maass, U. Immendoerfer, B. Koenig, U. Leser, B. Mueller, R. Goody, E. Pfaff, *Antimicrob. Agents Chemother.* **1993**, 37, 2612.
- [14] A. E. Ismail, A. A. Hamed, M. T. Abdel-Aal, I. Zeid, M. Al-Talib, Q. Wang, J. C. Jochims, *J. Prakt. Chem.* **1992**, 334, 661.
- [15] C. Sahlberg, R. Noreen, P. Engelhardt, M. Högberg, J. Kangasmetsa, L. Vrang, H. Zhang, *Bioorg. Med. Chem. Lett.* **1998**, 8, 1511.
- [16] M. Högberg, C. Sahlberg, P. Engelhardt, R. Noreen, J. Kangasmetsa, N. G. Johansson, B. Öberg, L. Vrang, H. Zhang, B. L. Sahlberg, T. Unge, S. Lövgren, K. Fridborg, K. Backbro, *J. Med. Chem.* **1999**, 42, 4150.
- [17] M. Popovic, M. G. Sarngadharan, E. Read, R. C. Gallo, *Science* **1984**, 224, 497.
- [18] S. Harada, Y. Koyanagi, N. Yamamoto, *Science* **1985**, 229, 563.
- [19] C. M. Nielsen, I. C. Bygbjerg, B. F. Vestergaard, *Lancet* **1987**, 1, 566.
- [20] F. W. Bell, A. S. Cantrell, M. Högberg, S. R. Jaskunas, N. G. Johansson, C. L. Jordan, M. D. Kinnick, P. Lind, J. M. Morin, Jr., R. Noreen, B. Öberg, J. A. Palkowitz, C. A. Parrish, P. Pranc, C. Sahlberg, R. J. Ternansky, R. T. Vasileff, L. Vrang, S. J. West, H. Zhang, X.-X. Zhou, *J. Med. Chem.* **1995**, 38, 4929.
- [21] R. Vig, C. Mao, T. K. Venkatachalam, L. Tuel-Ahlgren, E. A. Sudbeck, F. M. Uckun, *Bioorg. Med. Chem.* **1998**, 6, 1789.
- [22] T. Price, L. R. Creagh, L. Truitt, *J. Med. Chem.* **1965**, 8, 731.
- [23] J. B. Campbell, R. F. Dedinas, S. A. Trumbowerwalsh, *J. Org. Chem.* **1996**, 61, 620.